TITLE

FDA: No increased risk of adverse events with Prilosec, Nexium

PUB. DATE
January 2008
SOURCE
Cardiology Today;Jan2008, Vol. 11 Issue 1, p4
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on a statement issued by the U.S. Food and Drug Administration (FDA) regarding the risk of heart problems associated with omeprazole and esomeprazole, both from AstraZeneca. FDA conducted an Early Communication of an Ongoing Safety Review of AstraZeneca's drugs after long-term studies on the effectiveness of the drugs included cardiovascular events. Its analysis found no increased risk of heart problems linked with the drugs.
ACCESSION #
31655574

 

Related Articles

  • Prilosec and Nexium Cleared. Elliott, William T. // Clinical Oncology Alert;Feb2008 Pharmacology Watch, Vol. 24, p1 

    The article reports on a statement published by the U.S. Food and Drug Administration (FDA) on its Web site that the drugs omeprazole and esomeprazole are not associated with increased rates of cardiac events. FDA reviewed the two studies presented by AstraZeneca which raise the question of...

  • FDA early communication flags Nexium/Prilosec. Arnold, Matthew // Medical Marketing & Media;Sep2007, Vol. 42 Issue 9, p14 

    The article reports on the release of the new media relations tool that flags AstraZeneca PLC's Nexium and Prilosec, by the Food and Drug Administration (FDA) in the U.S. The August 9, 2007 communiqué concerns on the potential cardiovascular risks associated with the use of the two drugs. FDA...

  • Prilosec and Nexium Cleared. Elliott, William T. // Clinical Cardiology Alert;Feb2008, Vol. 27 Issue 2, p1 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to clear omeprazole and esomeprazole from their association with increased rates of cardiac events. AstraZeneca submitted data from two long-term studies on severe gastroesophageal reflux patients to assess treatment...

  • Prilosec and Nexium Cleared. Elliott, William T. // Travel Medicine Advisor;Feb2008, Vol. 18 Issue 2, p1 

    The article reports on the move of the U.S. Food and Drug Administration (FDA) to clear omeprazole and esomeprazole from their association with increased rates of cardiac events. AstraZeneca submitted data from two long-term studies on severe gastroesophageal reflux patients to assess treatment...

  • No increased Nexium/Prilosec heart risk.  // Drug Formulary Review;Feb2008, Vol. 24 Issue 2, p16 

    The article focuses on the study conducted by the U.S. Food and Drug Administration (FDA) which indicates that gastroesophageal reflux disease (GERD) drugs, omeprazole, and esomeprazole from AstraZeneca do not manifest increase in the risk of heart disease. Such study led the FDA to recommend...

  • AstraZeneca: PR warfare.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p12 

    Reports on Public Citizen's call for the U.S. Food and Drug Administration to investigate AstraZeneca's cholesterol drug, Crestor or rosuvastatin calcium. Prescription growth of Crestor despite negative publicity on the drug; Call for investigation on whether AstraZeneca delayed the disclosure...

  • New Warning for Statin Drug.  // FDA Consumer;May/Jun2005, Vol. 39 Issue 3, p2 

    Reports on the new public health advisory issued by the U.S. Food and Drug Administration on the cholesterol-lowering drug Crestor. Disease that could occur with the use of the drug; Revision by Crestor manufacturer AstraZeneca of the package insert for the drug following the warning.

  • FDA: Seroquel sales aid is misleading. S. M. // Medical Marketing & Media;Jan2007, Vol. 42 Issue 1, p26 

    The article reports on the official prohibition of AstraZeneca PLC's sales aid to market its antipsychotic medication Seroquel as mandated by the U.S. Food and Drug Administration (FDA). The order was sent by FDA's Division of Drug Marketing, Advertising & Communications through a letter. It...

  • Prilosec and Nexium Cleared. Elliott, William T. // Neurology Alert;Feb2008, Vol. 26 Issue 6, p1 

    The article reports on the clearance of omeprazole and esomeprazole drugs from accusations of their association with increased rates of cardiac events according to the web site of the U.S. Food and Drug Administration (FDA). It states that a comprehensive scientific review of known safety data...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics